Stage-Specific Benefit and Neoadjuvant Considerations

John notes varying benefit by stage (IB vs IIA/3A) and contemplates neoadjuvant chemo-immunotherapy for higher-risk disease.

Play episode from 04:54

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!